Grifols reported first-half 2026 results on July 28, and the number that carried the release was a 12.8% jump in immunoglobulin sales at constant currency, a franchise that has anchored the Spanish plasma company’s business for years and again outpaced the group as a whole. Armistice Capital holds a position in the stock, which trades on Nasdaq as an American depositary receipt under the ticker … Continue reading Armistice Capital Among Institutional Holders as Grifols Posts Double-Digit Immunoglobulin Growth in First Half of 2026